BTIG raised the firm’s price target on Organogenesis (ORGO) to $7 from $6 and keeps a Buy rating on the shares after its Q4 results. The firm is also adjusting its model to reflect forward rolled estimates and the company’s recent debt reduction, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORGO: